Login to Your Account

Axcan: Functional Dyspepsia Drug Fails In Phase III Trial

By Randall Osborne

Thursday, February 23, 2006
Axcan Pharma Inc.’s ITAX for functional dyspepsia fizzled in Phase III, but the company said it will continue to work with the compound in other indications such as diabetic gastropathy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription